Dynavax: Surge on Heplisav Phase III or Swine Flu? In early morning trading, Dynavax Technologies Corp. (DVAX) shares shot up dramatically (36%). However, we don't see a clear reason for that.The surge may be related to two pieces of news: phase III Heplisav data and the swine flu breakout.The first piece of news is about its phase III candidate Heplivsav. This morning, the company announced the oral presentation of additional phase III clinical data for Heplisav hepatitis B vaccine in a session for late-breaking abstracts at the 44th Annual Meeting of the European Association for the Study of Liver Disease (EASL) in Copenhagen, Denmark.In the presentation, Heplisav met its primary endpoint in this phase III trial and demonstrated the vaccine's potential to provide more rapid and increased protection against hepatitis B viral infection and with fewer doses than the licensed ...